The Influence of Chemotherapy-Induced Leucopenia (Cil) During Preoperative Chemotherapy (Pre-Cx) on Survival in Esophageal Squamous Cell Carcinoma (Escc) from the Results of Jcog9907

Hara, H. ; Ando, N. ; Igaki, H. ; Shinoda, M. ; Kato, K. ; Kitagawa, Y. ; Mizusawa, J. ; Nakamura, K.

Texto completo disponível

639PTHE INFLUENCE OF CHEMOTHERAPY-INDUCED LEUCOPENIA (CIL) DURING PREOPERATIVE CHEMOTHERAPY (PRE-CX) ON SURVIVAL IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) FROM THE RESULTS OF JCOG9907

Hara, H ; Ando, N ; Igaki, H ; Shinoda, M ; Kato, K ; Kitagawa, Y ; Mizusawa, J ; Nakamura, K

Oxford University Press

Texto completo disponível

Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)

Yamazaki, K. ; Nagase, M. ; Tamagawa, H. ; Ueda, S. ; Tamura, T. ; Murata, K. ; Eguchi Nakajima, T. ; Baba, E. ; Tsuda, M. ; Moriwaki, T. ; Esaki, T. ; Tsuji, Y. ; Muro, K. ; Taira, K. ; Denda, T. ; Funai, S. ; Shinozaki, K. ; Yamashita, H. ; Sugimoto, N. ; Okuno, T. ; Nishina, T. ; Umeki, M. ; Kurimoto, T. ; Takayama, T. ; Tsuji, A. ; Yoshida, M. ; Hosokawa, A. ; Shibata, Y. ; Suyama, K. ; Okabe, M. ; Suzuki, K. ; Seki, N. ; Kawakami, K. ; Sato, M. ; Fujikawa, K. ; Hirashima, T. ; Shimura, T. ; Taku, K. ; Otsuji, T. ; Tamura, F. ; Shinozaki, E. ; Nakashima, K. ; Hara, H. ; Tsushima, T. ; Ando, M. ; Morita, S. ; Boku, N. ; Hyodo, I.

England: Elsevier Ltd

Texto completo disponível

FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer

Tamura, K. ; Shimizu, C. ; Hojo, T. ; Akashi-Tanaka, S. ; Kinoshita, T. ; Yonemori, K. ; Kouno, T. ; Katsumata, N. ; Ando, M. ; Aogi, K. ; Koizumi, F. ; Nishio, K. ; Fujiwara, Y.

Oxford: Elsevier Ltd

Texto completo disponível

P-128 Liver metastasis affects progression pattern during immune checkpoint inhibitors monotherapy in gastric cancer

Motoo, I. ; Ando, T. ; Kajiura, S. ; Sakumura, M. ; Ueda, Y. ; Ueda, A. ; Suzuki, N. ; Nakada, N. ; Hosokawa, A. ; Yasuda, I.

Elsevier Ltd

Texto completo disponível

Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study

Yoshioka, H. ; Okamoto, I. ; Morita, S. ; Ando, M. ; Takeda, K. ; Seto, T. ; Yamamoto, N. ; Saka, H. ; Atagi, S. ; Hirashima, T. ; Kudoh, S. ; Satouchi, M. ; Ikeda, N. ; Iwamoto, Y. ; Sawa, T. ; Nakanishi, Y. ; Nakagawa, K.

Oxford: Elsevier Ltd

Texto completo disponível

Retrospective analysis of risk factor of injection site reaction induced by infusion of cisplatin plus vinorelbine

Ozawa, N. ; Hase, T. ; Hatta, T. ; Sagara, A. ; Ichikawa, K. ; Miyazaki, M. ; Ando, M. ; Yamada, K. ; Hasegawa, Y.

England: Elsevier Ltd

Texto completo disponível

Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104)

Takeda, K. ; Negoro, S. ; Tamura, T. ; Nishiwaki, Y. ; Kudoh, S. ; Yokota, S. ; Matsui, K. ; Semba, H. ; Nakagawa, K. ; Takada, Y. ; Ando, M. ; Shibata, T. ; Saijo, N.

Oxford: Elsevier Ltd

Texto completo disponível

Efficacy and safety of a recombinant soluble human thrombomodulin (ART-123) in preventing oxaliplatin induced peripheral neuropathy (OIPN): Results of a placebo-controlled, randomized, double-blind phase II study

Kato, T. ; Kotaka, M. ; Satake, H. ; Makiyama, A. ; Tsuji, Y. ; Shinozaki, K. ; Fujiwara, T. ; Mizushima, T. ; Harihara, Y. ; Nagata, N. ; Kurihara, N. ; Kagawa, Y. ; Kusakawa, G. ; Sakai, T. ; Uchida, Y. ; Takamoto, M. ; Asami, S. ; Ando, M. ; Saito, Y. ; Hyodo, I.

England: Elsevier Ltd

Texto completo disponível

1801P - A longitudinal tracking and quantitative assessment of paclitaxel-induced peripheral neurotoxicity

Matsuoka, A. ; Mitsuma, A. ; Maeda, O. ; Tsunoda, N. ; Kikumori, T. ; Ando, Y.

Elsevier Ltd

Texto completo disponível